Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Date publication

juin 2017

Journal

Journal of hematology & oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès

Tous les auteurs :
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28651604

Résumé

Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed.

Mots clés

Acute myeloid leukemia, Age, Lenalidomide, Myelodysplastic syndromes, del(5q)

Référence

J Hematol Oncol. 2017 Jun;10(1):131